Nektar Therapeutics Wins $115 Million Lawsuit Victory Over Eli Lilly
FROM THE WIRE · FINANCE.YAHOO.COM
Michigan-based investment advisor Cedar Grove Capital Management recently released its third-quarter 2026 investor letter. The letter can be downloaded here. In Q3 2026, Cedar Grove Capital Management's Multi-Strategy Composite returned -12.7%, trailing the Russell 2000 (-7.2%)…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishNektar's legal victory resolves a multi-year overhang and could support the stock price.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Nektar Therapeutics won a $115 million lawsuit against Eli Lilly.
- 02The victory resolves a multi-year overhang that has weighed on the stock.
- 03Cedar Grove Capital Management underperformed indices in Q3 2026 despite solid fundamentals.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Nektar Therapeutics39.27 USD-0.60%today -1.60%Positive Eli Lilly and Company1,203.08 USD-0.12%today +3.94%Negative Russell 20002,794.73+0.16%today -1.26%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets